Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celsion Corporation    CLSN

CELSION CORPORATION

(CLSN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

CELSION CORP : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
09/08/2020 | 08:37am EDT

Item 1.01. Entry into Material Definitive Agreement

On September 8, 2020, Celsion Corporation (the "Company" or "we", "our" or "us") entered into a Purchase Agreement (the "Purchase Agreement") and a Registration Rights Agreement (the "Registration Rights Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"), pursuant to which, upon the terms and subject to the conditions and limitations set forth therein, the Company has the right to sell to Lincoln Park up to $26.0 million of shares of the Company's common stock, par value $0.01 per share (the "Common Stock"), at the Company's discretion as described below (the "Offering").

Over the 36-month term of the Purchase Agreement, we have the right, but not the obligation, from time to time, in our sole discretion and subject to certain conditions, including that the closing price of our Common Stock is not below $0.25 per share, to direct Lincoln Park to purchase up to an aggregate amount of $26.0 million (subject to certain limitations) of shares of Common Stock. Under the Purchase Agreement, on any business day selected by us, we may direct Lincoln Park to purchase up to 400,000 shares (the "Regular Purchase Share Limit") of our Common Stock (each such purchase, a "Regular Purchase"). Lincoln Park's maximum obligation under any single Regular Purchase will not exceed $1,500,000, unless we mutually agree to increase the maximum amount of such Regular Purchase. The purchase price for shares of Common Stock to be purchased by Lincoln Park under a Regular Purchase will be the equal to the lower of (in each case, subject to the adjustments described in the Purchase Agreement): (i) the lowest sale price for our Common Stock on The Nasdaq Capital Market on the applicable purchase date, and (ii) the arithmetic average of the three lowest sale prices for our Common Stock on The Nasdaq Capital Market during the ten trading days prior to the purchase date.

If we direct Lincoln Park to purchase the maximum number of shares of Common Stock we then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, we may direct Lincoln Park to make an "accelerated purchase" of an additional amount of Common Stock that may not exceed the lesser of (i) 300% of the number of shares purchased pursuant to the corresponding Regular Purchase and (ii) 30% of the total number of shares of our Common Stock traded on The Nasdaq Capital Market during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.

The Purchase Agreement prohibits us from issuing or selling to Lincoln Park under the Purchase Agreement: (i) in excess of 6,688,588 shares of our Common Stock (the "Exchange Cap"), unless we obtain stockholder approval to issue shares in excess of the Exchange Cap or the average price of all applicable sales of our Common Stock to Lincoln Park under the Purchase Agreement equal or exceed the lower of (a) the Nasdaq Official Closing Price (as defined in the Purchase Agreement) immediately preceding the execution of the Purchase Agreement or (b) the average of the five Nasdaq Official Closing Prices for the Common Stock immediately preceding the execution of the Purchase Agreement, as adjusted in accordance with the rules of The Nasdaq Capital Market, and (ii) any shares of our Common Stock if those shares, when aggregated with all other shares of our Common Stock then beneficially owned by Lincoln Park and its affiliates would result in Lincoln Park and its affiliates having beneficial ownership of more than 9.99% of the then total outstanding shares of our Common Stock.

The Purchase Agreement does not limit our ability to raise capital from other sources at our sole discretion, except that we may not enter into any equity line or similar transaction for 36 months, other than an "at-the-market" offering. The Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties and agreements of us and Lincoln Park, indemnification rights and other obligations of the parties. We have the right to terminate the Purchase Agreement at any time on one business day's notice to Lincoln Park, at no cost to us.

As consideration for entering into the Purchase Agreement, we are issuing 437,828 shares of our Common Stock to Lincoln Park (the "Commitment Shares"). We will not receive any cash proceeds from the issuance of the Commitment Shares. Also pursuant to the Purchase Agreement, Lincoln Park has agreed to an initial purchase of 1,000,000 shares of our Common Stock for an aggregate purchase price of $1,000,000 or $1.00 per share. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our shares of Common Stock.

The Offering is being made pursuant to our effective Registration Statement on Form S-3 (File No. 333-227236) (the "Registration Statement"), which was previously filed with the SEC on September 7, 2018, and declared effective by the SEC on October 12, 2018, and the prospectus supplement related to the Offering filed with the SEC on September 8, 2020. Pursuant to the Registration Rights Agreement, under certain circumstances, if the Registration Statement is no longer available for use with respect to the Offering, we will be required to file additional registration statement(s).

We expect to use the proceeds from the Offering for continued research and development initiatives in connection with our product pipeline and for general corporate purposes.

The foregoing description of the Purchase Agreement and the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement and the Registration Rights Agreement, which are attached hereto as Exhibit 10.1 and 4.1, respectively, and incorporated by reference herein.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the shares, nor shall there be any offer, solicitation or sale of the shares in any state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.


Item 8.01 Other Events.


In connection with the Offering, Baker & McKenzie LLP has provided the Company with the opinion regarding legality of the Shares attached to this report as Exhibit 5.1.

On September 8, 2020, the Company issued a press release announcing the entry into the Purchase Agreement. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d)



Exhibit No.   Exhibit Name
4.1             Registration Rights Agreement, dated September 8, 2020, by and
              between Celsion Corporation and Lincoln Park Capital Fund, LLC
5.1             Opinion of Baker McKenzie LLP
10.1            Purchase Agreement, dated September 8, 2020, by and between
              Celsion Corporation and Lincoln Park Capital Fund, LLC
23.1            Consent of Baker McKenzie LLP (included in Exhibit 5.1)
99.1            Press release, dated September 8, 2020

© Edgar Online, source Glimpses


share with twitter share with LinkedIn share with facebook
All news about CELSION CORPORATION
10/16CELSION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rul..
AQ
10/12CELSION CORPORATION : Issues Letter to Stockholders
AQ
10/12Celsion Corporation Issues Letter to Stockholders
GL
09/08CELSION CORP : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
09/08CELSION : Announces Common Stock Purchase Agreement with Lincoln Park Capital an..
AQ
09/08Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital a..
GL
09/04CELSION CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/02CELSION CORP : Entry into a Material Definitive Agreement, Termination of a Mate..
AQ
09/02Celsion Corporation Restructures its Strategic Loan Facility
GL
08/14CELSION : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
More news
Financials (USD)
Sales 2020 0,51 M - -
Net income 2020 -19,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -0,85x
Yield 2020 -
Capitalization 20,5 M 20,5 M -
Capi. / Sales 2020 40,7x
Capi. / Sales 2021 82,2x
Nbr of Employees 29
Free-Float 98,6%
Chart CELSION CORPORATION
Duration : Period :
Celsion Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELSION CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 4,00 $
Last Close Price 0,57 $
Spread / Highest target 604%
Spread / Average Target 604%
Spread / Lowest Target 604%
EPS Revisions
Managers
NameTitle
Michael H. Tardugno Chairman, President & Chief Executive Officer
Jeffrey Wayne Church CFO, Secretary & SVP-Investor Relations
Nicholas Borys Chief Medical Officer & Senior Vice President
Khursheed Anwer Chief Scientific Officer & Executive VP
Pok Yu Chow Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELSION CORPORATION-66.77%21
GILEAD SCIENCES, INC.-6.82%75 938
REGENERON PHARMACEUTICALS53.57%61 364
VERTEX PHARMACEUTICALS-2.01%57 436
WUXI APPTEC CO., LTD.63.88%38 230
BEIGENE, LTD.80.92%27 326